Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant high blood pressure and heart failure, today announces the signature of an exclusive license and collaboration agreement with Qilu Pharmaceutical to develop and commercialize firibastat in China, including Hong Kong and Macao.
After a first partnership in Asia, this new agreement constitutes the second step of Quantum Genomics' partnership strategy in Asia.
Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau. Qilu Pharmaceutical also intends to join the Phase III study conducted in difficult-to-treat / resistant hypertension in China.
Quantum Genomics will receive upfront and milestone payments of up to $ 50 million as well as double-digit royalties on future sales of the firibastat.
The population suffering from difficult-to-treat and resistant arterial hypertension for the territories mentioned is between 25 and 30 million.
'Qilu Pharmaceutical is one of the leading pharmaceutical companies in China with 10 manufacturing sites in its domestic territory as well as 5 R&D centers in the United States and China. Qilu Pharmaceutical, which has launched more than 200 products in China, is a 'leading' player in the cardiovascular field and has established long-term partnerships with international companies. With a full sales network and an experienced marketing team, Qilu Pharmaceutical is a partner of choice and we look forward to working with the team, 'said Jean-Philippe Milon, CEO of Quantum Genomics.
'Quantum Genomics is a leading biopharmaceutical company, specializing in the development of a new class of drugs based on the central mechanism of inhibition of aminopeptidase A,' said Dr. Binhui (Ben) Ni, Chief Business & Investment Officer, Corporate Vice-President of Qilu Pharmaceutical,'The development of Firibastat, the first cerebral aminopeptidase A inhibitor currently being developed to treat high blood pressure alone or in combination with other antihypertensive drugs, offers a real alternative to meet important needs hitherto. satisfied in China. We are confident in the ability of this new treatment, which is supported by solid clinical data, to have a positive impact on the lives of patients. '
About Qilu Pharmaceutical
Qilu Pharmaceutical is one of the leading pharmaceutical companies in China, with a mission to care for people through science and technology. The company develops, manufactures and markets new drugs or biologics, as well as generics and biosimilars. Qilu has 12 subsidiaries and 10 manufacturing sites with more than 23,000 employees worldwide and has launched more than 200 products in China generating sales of over $ 3.3 billion in 2019.
Qilu Pharmaceutical is one of the world's leading manufacturers, in compliance with Good Manufacturing Practices, major agency regulations, and exports its products, including active pharmaceutical ingredients and formulations to over 70 countries.
With the commitment to develop innovative medicines for solutions that improve patients' lives and address unmet medical needs in multiple therapeutic areas, Qilu employs more than 2,000 dedicated scientists and a comprehensive clinical team who work in its centers. R&D in the United States and China. The company is in constant search of partnership with global players via an in / out-licensing and / or co-development strategy.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of cerebral Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it is based on more than twenty years of research work from the University of Paris-Descartes and the INSERM / CNRS laboratory led by Dr. Catherine Llorens-Cortes at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (around 30% of patients are poorly controlled or have failed treatment), and Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and listed on the US OTCQX market (symbol: QNNTF).
Contact:
Nathalie Boumendil
Tel: 06 85 82 41 95
Email: nathalie@so-bang.fr
QUANTUM GENOMICS 
